Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

Detected CMS Systems:

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s00432-013-1411-7.

Title:
Serum HER-2: sensitivity, specificity, and predictive values for detecting metastatic recurrence in breast cancer patients | Journal of Cancer Research and Clinical Oncology
Description:
The aim of this study was to determine the sensitivity, specificity, and predictive values of serum HER-2 for detecting metastatic recurrence in breast cancer patients. In the period 2004–2009, serum HER-2 was measured in 1,348 patients with breast cancer: 837 during routine controls at the Oncology Department and 511 newly diagnosed. The patients with positive serum HER-2, all the newly diagnosed and 1/5 of the patients with negative serum HER-2 were followed with serum HER-2 measurements every 3–12 months using the ADVIA Centaur assay. Tissue HER-2 status was determined by IHC and FISH. Patients with a single serum HER-2 value above 15 μg/L were considered serum positive. Metastases were diagnosed according to the routine clinical methods using imaging/biopsy. Of the 862 patients included, 21 had unavailable medical records and were excluded. Patients with unknown tissue status (218), missing blood sample before recurrence (74), or presenting with primary metastatic disease (9) were also excluded. Blood samples before the detection of metastatic recurrence were available in 154 tissue HER-2-positive and in 386 tissue HER-2-negative patients. The sensitivity, specificity, positive and negative predictive values in tissue HER-2-positive patients with values above 15 μg/L were 69 % (95 % CI 53–80 %), 71 % (62–78), 47 % (35–59), and 86 % (77–91), respectively. Combining the cutoff value of 15 μg/L with a delta value of >100 % increase from individual baseline after primary therapy, or increasing the cutoff to 32 μg/L raises the specificity to 96 %, but lowers the sensitivity to 50 and 47 %, respectively. Preoperative serum HER-2 values were accessible in 69 tissue-positive patients, but no significant association was found with later development of metastases. The sensitivity, specificity, positive and negative predictive values in tissue HER-2-negative patients with values above 15 μg/L were 33 % (21–47), 77 % (73–82), 18 % (12–27), and 88 % (84–91), respectively. Monitoring tissue HER-2-positive breast cancer patients with serum HER-2 has a sufficient sensitivity to detect metastatic recurrence, while its use in monitoring of tissue HER-2-negative patients is unsatisfactory.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Health & Fitness
  • Education
  • Family & Parenting

Content Management System {📝}

What CMS is link.springer.com built with?


Link.springer.com is built with PLONE.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

cancer, breast, google, scholar, pubmed, article, serum, patients, cas, clin, clinical, metastatic, herneu, chem, sensitivity, values, levels, med, lab, recurrence, tissue, monitoring, oncol, denmark, research, specificity, brandslund, access, human, extracellular, domain, predictive, sørensen, madsen, therapy, cerbb, neumann, res, privacy, cookies, content, journal, oncology, jakobsen, positive, μgl, data, publish, search, patricia,

Topics {✒️}

month download article/chapter cyclophosphamide ct/ul/mr human c-erbb-2 gene erbb-homologous gene distinct her2-low versus her2 rikke fredslund andersen serum c-erb-2 levels her2-positive breast cancer full article pdf related subjects patricia diana sørensen human breast cancer privacy choices/manage cookies 2/neu predicts response jonna skov madsen erik hugger jakobsen c-erbb-2 oncoprotein metastatic breast cancer da silva mm independent prognostic factor trastuzumab-based therapy breast cancer patients primary breast cancer diagnostic strategies serum her2 testing carney wp erbb-2 protein overexpression article sørensen regional health research european economic area eva brix petersen unavailable medical records tyrosine kinase activity 2/neu diagnostics receiver operated characteristics death knell tolls tumour biol 18 biol markers 19 yang-feng tl conditions privacy policy trastuzumab-based treatment article journal advia centaur assay negative predictive values sørensen pd olsen da routine oncology setting 2/ecd analysis clinical oncology aims clinical oncology/college

Questions {❓}

  • Fang L, Barekati Z, Zhang B, Liu Z, Zhong X (2011) Targeted therapy in breast cancer: what’s new?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Serum HER-2: sensitivity, specificity, and predictive values for detecting metastatic recurrence in breast cancer patients
         description:The aim of this study was to determine the sensitivity, specificity, and predictive values of serum HER-2 for detecting metastatic recurrence in breast cancer patients. In the period 2004–2009, serum HER-2 was measured in 1,348 patients with breast cancer: 837 during routine controls at the Oncology Department and 511 newly diagnosed. The patients with positive serum HER-2, all the newly diagnosed and 1/5 of the patients with negative serum HER-2 were followed with serum HER-2 measurements every 3–12 months using the ADVIA Centaur assay. Tissue HER-2 status was determined by IHC and FISH. Patients with a single serum HER-2 value above 15 μg/L were considered serum positive. Metastases were diagnosed according to the routine clinical methods using imaging/biopsy. Of the 862 patients included, 21 had unavailable medical records and were excluded. Patients with unknown tissue status (218), missing blood sample before recurrence (74), or presenting with primary metastatic disease (9) were also excluded. Blood samples before the detection of metastatic recurrence were available in 154 tissue HER-2-positive and in 386 tissue HER-2-negative patients. The sensitivity, specificity, positive and negative predictive values in tissue HER-2-positive patients with values above 15 μg/L were 69 % (95 % CI 53–80 %), 71 % (62–78), 47 % (35–59), and 86 % (77–91), respectively. Combining the cutoff value of 15 μg/L with a delta value of >100 % increase from individual baseline after primary therapy, or increasing the cutoff to 32 μg/L raises the specificity to 96 %, but lowers the sensitivity to 50 and 47 %, respectively. Preoperative serum HER-2 values were accessible in 69 tissue-positive patients, but no significant association was found with later development of metastases. The sensitivity, specificity, positive and negative predictive values in tissue HER-2-negative patients with values above 15 μg/L were 33 % (21–47), 77 % (73–82), 18 % (12–27), and 88 % (84–91), respectively. Monitoring tissue HER-2-positive breast cancer patients with serum HER-2 has a sufficient sensitivity to detect metastatic recurrence, while its use in monitoring of tissue HER-2-negative patients is unsatisfactory.
         datePublished:2013-03-13T00:00:00Z
         dateModified:2013-03-13T00:00:00Z
         pageStart:1005
         pageEnd:1013
         sameAs:https://doi.org/10.1007/s00432-013-1411-7
         keywords:
            Breast cancer
            Metastases
            Predictive values
            Sensitivity
            Serum HER-2
            Specificity
            Oncology
            Cancer Research
            Internal Medicine
            Hematology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-013-1411-7/MediaObjects/432_2013_1411_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-013-1411-7/MediaObjects/432_2013_1411_Fig2_HTML.gif
         isPartOf:
            name:Journal of Cancer Research and Clinical Oncology
            issn:
               1432-1335
               0171-5216
            volumeNumber:139
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Patricia Diana Sørensen
               affiliation:
                     name:Lillebaelt Hospital
                     address:
                        name:Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark
                        type:PostalAddress
                     type:Organization
                     name:University of Southern Denmark
                     address:
                        name:Faculty of Health Sciences, Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Erik Hugger Jakobsen
               affiliation:
                     name:Lillebaelt Hospital
                     address:
                        name:Department of Clinical Oncology, Lillebaelt Hospital, Vejle, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jonna Skov Madsen
               affiliation:
                     name:Lillebaelt Hospital
                     address:
                        name:Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark
                        type:PostalAddress
                     type:Organization
                     name:University of Southern Denmark
                     address:
                        name:Faculty of Health Sciences, Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Eva Brix Petersen
               affiliation:
                     name:Lillebaelt Hospital
                     address:
                        name:Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rikke Fredslund Andersen
               affiliation:
                     name:Lillebaelt Hospital
                     address:
                        name:Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Birthe Østergaard
               affiliation:
                     name:Lillebaelt Hospital
                     address:
                        name:Department of Clinical Pathology, Lillebaelt Hospital, Vejle, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ivan Brandslund
               affiliation:
                     name:Lillebaelt Hospital
                     address:
                        name:Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark
                        type:PostalAddress
                     type:Organization
                     name:University of Southern Denmark
                     address:
                        name:Faculty of Health Sciences, Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Serum HER-2: sensitivity, specificity, and predictive values for detecting metastatic recurrence in breast cancer patients
      description:The aim of this study was to determine the sensitivity, specificity, and predictive values of serum HER-2 for detecting metastatic recurrence in breast cancer patients. In the period 2004–2009, serum HER-2 was measured in 1,348 patients with breast cancer: 837 during routine controls at the Oncology Department and 511 newly diagnosed. The patients with positive serum HER-2, all the newly diagnosed and 1/5 of the patients with negative serum HER-2 were followed with serum HER-2 measurements every 3–12 months using the ADVIA Centaur assay. Tissue HER-2 status was determined by IHC and FISH. Patients with a single serum HER-2 value above 15 μg/L were considered serum positive. Metastases were diagnosed according to the routine clinical methods using imaging/biopsy. Of the 862 patients included, 21 had unavailable medical records and were excluded. Patients with unknown tissue status (218), missing blood sample before recurrence (74), or presenting with primary metastatic disease (9) were also excluded. Blood samples before the detection of metastatic recurrence were available in 154 tissue HER-2-positive and in 386 tissue HER-2-negative patients. The sensitivity, specificity, positive and negative predictive values in tissue HER-2-positive patients with values above 15 μg/L were 69 % (95 % CI 53–80 %), 71 % (62–78), 47 % (35–59), and 86 % (77–91), respectively. Combining the cutoff value of 15 μg/L with a delta value of >100 % increase from individual baseline after primary therapy, or increasing the cutoff to 32 μg/L raises the specificity to 96 %, but lowers the sensitivity to 50 and 47 %, respectively. Preoperative serum HER-2 values were accessible in 69 tissue-positive patients, but no significant association was found with later development of metastases. The sensitivity, specificity, positive and negative predictive values in tissue HER-2-negative patients with values above 15 μg/L were 33 % (21–47), 77 % (73–82), 18 % (12–27), and 88 % (84–91), respectively. Monitoring tissue HER-2-positive breast cancer patients with serum HER-2 has a sufficient sensitivity to detect metastatic recurrence, while its use in monitoring of tissue HER-2-negative patients is unsatisfactory.
      datePublished:2013-03-13T00:00:00Z
      dateModified:2013-03-13T00:00:00Z
      pageStart:1005
      pageEnd:1013
      sameAs:https://doi.org/10.1007/s00432-013-1411-7
      keywords:
         Breast cancer
         Metastases
         Predictive values
         Sensitivity
         Serum HER-2
         Specificity
         Oncology
         Cancer Research
         Internal Medicine
         Hematology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-013-1411-7/MediaObjects/432_2013_1411_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-013-1411-7/MediaObjects/432_2013_1411_Fig2_HTML.gif
      isPartOf:
         name:Journal of Cancer Research and Clinical Oncology
         issn:
            1432-1335
            0171-5216
         volumeNumber:139
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Patricia Diana Sørensen
            affiliation:
                  name:Lillebaelt Hospital
                  address:
                     name:Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark
                     type:PostalAddress
                  type:Organization
                  name:University of Southern Denmark
                  address:
                     name:Faculty of Health Sciences, Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Erik Hugger Jakobsen
            affiliation:
                  name:Lillebaelt Hospital
                  address:
                     name:Department of Clinical Oncology, Lillebaelt Hospital, Vejle, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jonna Skov Madsen
            affiliation:
                  name:Lillebaelt Hospital
                  address:
                     name:Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark
                     type:PostalAddress
                  type:Organization
                  name:University of Southern Denmark
                  address:
                     name:Faculty of Health Sciences, Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Eva Brix Petersen
            affiliation:
                  name:Lillebaelt Hospital
                  address:
                     name:Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rikke Fredslund Andersen
            affiliation:
                  name:Lillebaelt Hospital
                  address:
                     name:Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Birthe Østergaard
            affiliation:
                  name:Lillebaelt Hospital
                  address:
                     name:Department of Clinical Pathology, Lillebaelt Hospital, Vejle, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ivan Brandslund
            affiliation:
                  name:Lillebaelt Hospital
                  address:
                     name:Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark
                     type:PostalAddress
                  type:Organization
                  name:University of Southern Denmark
                  address:
                     name:Faculty of Health Sciences, Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Journal of Cancer Research and Clinical Oncology
      issn:
         1432-1335
         0171-5216
      volumeNumber:139
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Lillebaelt Hospital
      address:
         name:Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark
         type:PostalAddress
      name:University of Southern Denmark
      address:
         name:Faculty of Health Sciences, Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark
         type:PostalAddress
      name:Lillebaelt Hospital
      address:
         name:Department of Clinical Oncology, Lillebaelt Hospital, Vejle, Denmark
         type:PostalAddress
      name:Lillebaelt Hospital
      address:
         name:Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark
         type:PostalAddress
      name:University of Southern Denmark
      address:
         name:Faculty of Health Sciences, Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark
         type:PostalAddress
      name:Lillebaelt Hospital
      address:
         name:Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark
         type:PostalAddress
      name:Lillebaelt Hospital
      address:
         name:Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark
         type:PostalAddress
      name:Lillebaelt Hospital
      address:
         name:Department of Clinical Pathology, Lillebaelt Hospital, Vejle, Denmark
         type:PostalAddress
      name:Lillebaelt Hospital
      address:
         name:Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark
         type:PostalAddress
      name:University of Southern Denmark
      address:
         name:Faculty of Health Sciences, Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Patricia Diana Sørensen
      affiliation:
            name:Lillebaelt Hospital
            address:
               name:Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark
               type:PostalAddress
            type:Organization
            name:University of Southern Denmark
            address:
               name:Faculty of Health Sciences, Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Erik Hugger Jakobsen
      affiliation:
            name:Lillebaelt Hospital
            address:
               name:Department of Clinical Oncology, Lillebaelt Hospital, Vejle, Denmark
               type:PostalAddress
            type:Organization
      name:Jonna Skov Madsen
      affiliation:
            name:Lillebaelt Hospital
            address:
               name:Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark
               type:PostalAddress
            type:Organization
            name:University of Southern Denmark
            address:
               name:Faculty of Health Sciences, Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark
               type:PostalAddress
            type:Organization
      name:Eva Brix Petersen
      affiliation:
            name:Lillebaelt Hospital
            address:
               name:Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark
               type:PostalAddress
            type:Organization
      name:Rikke Fredslund Andersen
      affiliation:
            name:Lillebaelt Hospital
            address:
               name:Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark
               type:PostalAddress
            type:Organization
      name:Birthe Østergaard
      affiliation:
            name:Lillebaelt Hospital
            address:
               name:Department of Clinical Pathology, Lillebaelt Hospital, Vejle, Denmark
               type:PostalAddress
            type:Organization
      name:Ivan Brandslund
      affiliation:
            name:Lillebaelt Hospital
            address:
               name:Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark
               type:PostalAddress
            type:Organization
            name:University of Southern Denmark
            address:
               name:Faculty of Health Sciences, Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark
      name:Faculty of Health Sciences, Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark
      name:Department of Clinical Oncology, Lillebaelt Hospital, Vejle, Denmark
      name:Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark
      name:Faculty of Health Sciences, Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark
      name:Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark
      name:Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark
      name:Department of Clinical Pathology, Lillebaelt Hospital, Vejle, Denmark
      name:Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark
      name:Faculty of Health Sciences, Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(132)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

CDN Services {📦}

  • Crossref

3.97s.